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Background: Opioids are one of the most prescribed treatments for chronic pain 
(CP). However, their long-term use (>3 months) has been surrounded by controversy, 
due to loss of beneficial effects.
Objective: To explore the experiences of people with chronic non-malignant low 
back pain in Spain undergoing long-term treatment with opioids.
Design: Qualitative study.
Setting and participants: We conducted 15 semi-structured interviews at the Pain 
Clinic with persons taking opioid treatment.
Methods: The interviews were analysed by qualitative content analysis as described 
by Graneheim and Lundman, and developed categories and themes discussed in light 
of a biomedicalization framework.
Main results: We developed one overarching theme—Living with opioids: dependence 
and autonomy while seeking relief—and three categories: The long pathway to opioids 
due to the invisibility of pain; Opioids: from blind date to a long-term relationship; and 
What opioids cannot fix.
Discussion: The long and difficult road to find effective treatments was a fundamen-
tal part of coping with pain, involving long-term relationships with the health system. 
This study reflects the benefits, and drawbacks of opioids, along with struggles to 
maintain autonomy and make decisions while undergoing long-term treatment with 
opioids. The paper also highlights the consequences of pain in the economy, family 
and social life of patients.
Conclusions: Patients' experiences should be considered to a greater extent by 
health-care professionals when giving information about opioids and setting treat-
ment goals. Greater consideration of the social determinants of health that affect CP 
experiences might lead to more effective solutions to CP.
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1  | INTRODUC TION
Chronic pain (CP), defined as pain that persists beyond the normal 
tissue healing time (3 months as a convenient cut-off point), is a 
health problem that has reached epidemic proportions worldwide. 
The average CP prevalence is 27% in European countries, consis-
tent with international estimates.1 In Spain, around 17% of the 
population suffer from this illness, making it a major health-care 
problem.2
Opioids are one of the most prescribed analgesic pharmaco-
logical treatments for CP.3 Prescriptions for opioids have increased 
dramatically in the last few decades, numbers being far higher in 
countries such as the United States or Canada.4 According to the 
National American Survey on Drug Use and Health (NSDUH) report 
in 2016, more than one-third of American adults were prescribed 
opioids.5 Although to a lesser extent, an increase has also been ob-
served in some European countries,6-8 including Spain (83.59% from 
2008 to 2015).9
Opioid therapy has been found to be associated with the al-
leviation of pain in the short term.10 However, their prescription 
for long-term use sometimes presents a dilemma,11 since it has 
been accompanied by a great increase in overdoses, abuse, ad-
diction and recreational use in some countries such as the United 
States.12 Clinicians therefore face the potentially conflicting du-
ties of relieving pain on the one hand, viewed worldwide as an 
ethical medical obligation,13 and preventing the potential harm 
to the patient of long-term opioid consumption on the other.14 
Dispelling the myriad myths associated with pain and fears asso-
ciated with opioid prescription is no easy matter. Part of the solu-
tion depends on educating and training health-care professionals 
in pain management.15
Patients who experience CP could also face this quandary since 
opioids have been related to negative side effects, such as exces-
sive sedation, respiratory failure, urinary retention or constipation.16 
These side effects, along with social, cultural and historical factors, 
have given rise to a set of attitudes and beliefs regarding the dele-
terious effects of opioid administration for pain relief.17 The main 
reasons for this inappropriate set of attitudes and beliefs are the lack 
of knowledge regarding opioids and the stigmatization that some pa-
tients felt when prescribed opioids.18
The benefits of opioids have also been surrounded by con-
troversy.19 Some studies20,21 have shown that most people using 
opioids continue to report moderate or severe pain, and that 
functional improvements are often limited. Other authors22 have 
shown that increases in the intensity of pain are connected with 
skipping doses, since patients reduce or stop taking their opioid 
therapy to avoid side effects. Despite the existence of clinical 
guidelines that regulate the correct use of opioids in the treat-
ment of pain,23,24 in Spain, CP management still remains weak.25 
Fear of addiction might be an important reason why CP is often 
undertreated.16
Recent literature18,26-28 has explored the experience of adults 
using prescription opioids to manage CNCP, concluding that there 
were many negative aspects to using opioids daily, in most cases 
these were outweighed by the positive effects, and most of the neg-
ative aspects were socioculturally induced rather than caused by the 
drug itself. However, these studies have been carried out in coun-
tries such as the United States or Canada, where the trend of opioid 
use has been accompanied by an increase in reported opioid abuse 
and opioid-related death29 which is a different situation compared 
to Spain.30-33
Considering the potential worries and difficulties associated with 
the use of opioids, it is very important that patients communicate 
and relate to health-care providers their experience with opioids in 
an open and effective manner. However, although the number of 
individuals living with CP and taking opioids is increasing, to the 
best of our knowledge, no study has been performed to explore the 
experiences of patients taking opioid medications in Spain. Thus, 
this study aims to fill this gap in knowledge by exploring the experi-
ences of patients with CP receiving long-term treatment (more than 
3 months) with opioids in Spain.
1.1 | Spanish health-care system
The Spanish health-care system has universal coverage, is almost 
entirely funded by taxes and is free of charge at the point of de-
livery, except for pharmaceutical products for people under 65, 
which require a copayment of 40% of their price. Provision of care 
is predominantly within the public network of health-care facilities. 
Primary health care is the first point of contact for individuals with 
the health-care system, and thus, professionals working there as 
GPs, nurses and midwifes act as gatekeepers of the system. The pri-
mary health-care network is an integrated part of the public systems 
through mutually supportive referral systems with secondary and 
tertiary health-care facilities. In the case of patients who experience 
CP, after visiting their GP they are referred to a specialist, usually a 
rheumatologist or traumatologist, and then to the Pain Clinic if the 
pain does not remit.
The Pain Clinic is a unit specialized in the management and treat-
ment of all complex types of pain conditions, especially in those pa-
tients who do not respond to conventional treatment and those who 
require special drugs or treatment techniques, such as local infiltra-
tion of anaesthetics and/or steroids or radiofrequency neurolysis.
Opioid treatments can be prescribed by GPs or specialist doctors. 
All official opioid prescriptions must include the denomination ‘Official 
Narcotics Prescription’, with the exception of those that are issued in 
electronic format. In each Official Narcotics Prescription, only one type 
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of opioid treatment must be prescribed, with a maximum treatment 
length of 3 months and without exceeding a total of four containers.
1.2 | Theoretical framework
CP is considered to be a complex biopsychosocial event.34 Besides 
the physical experience of pain, individuals suffering from CP often 
experience mental and emotional disturbances and their family en-
vironment might also be severely affected.35 Given its complexity, 
health-care services should address CP following a multidisciplinary 
approach, although pharmacological therapy is still considered the cor-
nerstone (and sometimes the only approach) of the control of pain.36 
Moreover, as we have previously described, long-term treatment with 
opioids might help to relieve pain in some cases, but result in other 
issues related not only with adverse effects, but also with communica-
tion, negotiation and power relationship problems between patients 
and providers, stigma and the role of family and support networks. 
Following an emergent design, a biomedicalization framework was 
chosen, meaning that the analysis of the interviews guided the choice 
of theory. Thus, the theoretical framework was mainly used in the 
discussion section to contrast the results of this study with previous 
evidence and to frame participants' experiences in the wider context 
of health care. Biomedicalization was described by Clarke et al (2003) 
as the ‘increasingly complex, multi-sited, multidirectional processes of 
medicalization, both extended and reconstituted through the new so-
cial forms of highly technoscientific biomedicine’. Biomedicalization is 
driven by and at the same time fosters five key overlapping processes: 
major shifts in health and health-care policies and funding; the focus 
on health itself and elaboration of risk and surveillance biomedicines; 
technoscientization of biomedicine; major changes in the production 
and consumption of biomedical knowledge; and transformation of 
bodies and new individual and collective identities. The results of this 
study are better understood and explained in the light of this frame-
work as we will explain in the Discussion section.
2  | MATERIAL AND METHODS
2.1 | Study design
This is a qualitative study in which data were collected through 15 
semi-structured interviews to explore the experiences of chronic 
low back pain (CLBP) patients taking opioids to treat their pain. 
Individual interviews were analysed by qualitative content analysis 
as applied in health sciences research.37
2.2 | Participants and data collection
The study protocol was approved by the Clinical Research Ethics 
Committee of the ‘Puerta del Mar’ University Hospital (Cádiz, Spain), 
ensuring compliance with the standards of good clinical practice.
Recruitment and data collection were conducted from April to 
October 2018. The participants were recruited from the Pain Clinic 
in Hospital Puerta del Mar. Inclusion criteria for the study were as 
follows: adults suffering from chronic non-malignant low back pain 
and receiving long-term treatment (over 3 months) with opioids. 
Patients taking opioids for less than 3 months or with another pain 
origin than chronic non-cancer low back pain were not included.
All the patients were recruited after a routine physical evalua-
tion in their medical visit to the Pain Clinic. Previously, their medi-
cal data, including information on prescribed medications from the 
records, were evaluated and discussed by the clinician and inter-
viewer. If the person met the inclusion criteria after an analysis of 
their medical records and their medical visit and physical evaluation, 
the clinician explained to him or her the aim of the study. All seven-
teen eligible patients were approached by the clinician. After this 
initial approach by the clinician, the interviewer met the potential 
participant and they went to a quieter place in a clinical setting for 
the interview, before with the participant was shown a letter with 
more comprehensive information about the study and its aim. The 
participants were left alone to read and think carefully before giving 
their written informed consent. When they finished reading it, they 
had the opportunity to ask questions about the study, after which 
the interview took place. At this stage, two people rejected the par-
ticipation, alluding to lack of time. Individual, semi-structured, qual-
itative interviews following a guide were conducted in Spanish. The 
guide was based on open-ended questions developed with guidance 
from the literature regarding chronic pain experiences and factors 
associated with the use of opioids (Table 1). Aspects related to the 
origin of their pain, opioid belief, information received about treat-
ment, opioid experience, their family and social support were also 
of particular interest. If a specific topic that was not included in the 
first version of the interview guide came to light spontaneously in 
a specific interview, it was added and asked in the subsequent in-
terviews. Interviews were audio-recorded, transcribed verbatim and 
anonymized. All names used here are pseudonyms. We conducted 
interviews until very similar experiences were described in the last 
interviews as in the previous interviews.
2.3 | Analysis
We adopted a constructionist perspective. We analysed all the inter-
view transcripts following qualitative content analysis as described 
by Graneheim and Lundman.37 The data analysis was inductive, and 
thus, the category construction was data-driven; no initial hypoth-
esis guided the preliminary coding and subsequent development of 
categories. However, in the analysis of the results presented in the 
Discussion section, we followed the biomedicalization framework 
described above.
Interview transcripts were entered into Atlas.ti 1.0.16 to sup-
port the coding process. At the beginning of each interview tran-
script, a brief log of the interview was written, including information 
about the time, duration, and the feelings and perceptions of the 
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interviewer during the conversation in order to help with the anal-
ysis process. The researcher who conducted the interviews tran-
scribed them verbatim.
To carry out the qualitative content analysis, two researchers 
read the transcripts independently and assigned codes line-by-line to 
meaningful pieces of the interview transcripts. Then, the research-
ers met to compare and refine codes, which were then grouped into 
categories. The material was grouped into three key categories, 
which were further validated after re-analysis of all the interviews. 
Coding maps were used to help with the code grouping and the anal-
ysis of relationships between the emerging categories and codes. In 
the last step, an overarching theme involving these three categories 
was identified. The analysis was conducted in Spanish, and quotes 
were chosen from this material to be translated into English. All the 
authors understand both languages and, thus, were able to partici-
pate in the whole analysis process.
Our positions as researchers have continuously been discussed 
in relation to ethical considerations and questions about responsi-
bility. In line with Graneheim and Lundman (2004),37 we argue that, 
in qualitative content analysis, interpretation involves a balancing 
act of providing interpretation while at the same time making sure 
that our interpretations remain always grounded on the data. By 
providing a thorough explanation of the analytical process, our in-
tention is to allow the reader to assess the study's usefulness and 
transferability.
3  | RESULTS
Fifteen people aged from 40 to 88 were interviewed (9 women and 6 
men). One participant had completed higher education and the rest 
elementary education. Four had a declaration of total disability to 
work, two were on sick leave, and nine were retired or unemployed. 
Thirteen were prescribed a treatment with a strong opioid, one of 
the two who were taking weak opioids had a PRN order (Table 2 
near here).
From the analysis, one overarching theme was developed: ‘Living 
with opioids: dependence and autonomy while seeking relief’, which 
crosscut three categories: ‘The long pathway to opioids due to the 
invisibility of pain’; ‘opioids: from blind date to a long-term relation-
ship’; and ‘what opioids cannot fix’.
The quest for effective treatment was a fundamental part of 
the participants' struggle to cope with the pain, and it involved 
long-term relationships with the health system. In relation to this, 
the theme ‘living with opioids: dependence and autonomy while 
seeking relief’ refers to how navigating the health system meant 
that the study participants were dependent on health-care profes-
sionals exercising their power to refer them to specialized care to 
get access to a diagnosis and treatment, including opioids. At the 
same time, it also meant having, to a certain extent, room to make 
decisions, to exercise autonomy, despite having little information 
and meeting professionals that hardly coordinated/communicated 
with each other.
The two first categories ‘the long pathway to opioids due to 
the invisibility of pain’ and ‘opioids: from blind date to a long-term 
relationship’ refer to the journey participants made to get a di-
agnosis and treatment with opioids, and their experiences during 
this long and difficult process, which was quite unique for each 
person. The third category, ‘what opioids cannot fix’, describes the 
circumstances and situations experienced by the patients before 
and after the painful episode started, and how they have influ-
enced the whole process. In this case, opioids do not have any ef-
fect since they are not enough to remedy the deficiencies derived 
from these situations.
TA B L E  1   Interview guide used for the semi-structured 
interviews
Exploring pain
How did the pain start?
Exploring prescription of opioids and information
Can you tell me about how you started taking opioids?
How did your doctor suggest taking these medications?
How did you react when your doctor told you that you will be 
taking an opioid treatment?
What was your opinion about opioid medications before taking it? 
And now? Has your opinion changed?
Were other alternatives considered? Which ones?
What type of information about opioids have you received?
What is your opinion about the information that your doctor gave 
you about the treatment?
Have you sought information through other means? Which ones?
Daily life and opioids
Can you describe a usual day in your life?
Since you started this treatment with opioids, have you changed 
your daily activities?
Since you started this treatment with opioids, could you describe 
how your health is?
Could you describe your mood since you started this treatment 
with opioids?
Do you think that opioids cause side effects? How?
Taking opioids
Have you ever tried to stop or decrease the opioid dose? Why? 
How was the experience?
Since you started this treatment, have you needed to increase 
the dose? Do you think you would have needed to increase the 
doses? Why?
What is the best way to relieve your pain?
Social relationships and work
How is your social life since you are under an opioid treatment?
Can you describe the relationship with your family? Has this 
relationship changed since you are under treatment?
Can you describe your working life?
Final questions
How is your experience with opioid treatments In general?
Would you like to add anything else?
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3.1 | The long pathway to opioids due to the 
invisibility of pain
This first category describes the long and difficult pathway that par-
ticipants followed from the onset of their pain until getting treatment 
with opioids. This journey could start as soon as early adolescence 
(Table 3).
For the participants, the fact that pain ‘cannot be seen’ explained 
such a lengthy journey to obtain diagnosis and prescriptions. They 
mentioned numerous consequences of this invisibility of pain in in-
dividual and social spheres, as well as in their encounters with the 
health-care system. At the individual level, the invisibility of pain 
meant that it could be ignored or minimized by those suffering from 
it. As Alejandro (51 years old, 4 years of taking morphine) said, ‘mine 
[pain] was caused by work, by lifting weight, my back started hurt-
ing, and… I was walking and limping, and I thought it was…well, noth-
ing. I thought it will go away. By the time I realized and went to the 
doctor, I was using crutches’.
In the social arena, the long history of pain, together with the 
lack of physical signs, could lead, in the view of participants, to indif-
ference or a lack of empathy. As Hugo (52 years old, 5 years of taking 
morphine) claimed, ‘my family say that I'm exaggerating’. Relatives 
and friends were described as having got used to seeing partici-
pants in pain and therefore minimized its importance. Participants 
described the difficulty in lending credibility to the severity of the 
problem when there were no physical signs. As Rafael (52 years old, 
5 years of taking tapentadol) put it: ‘They've seen me in pain for 
so long… I think ‘if they could know how much pain I feel' but they 
see me every day in the same situation and they've become used to 
seeing me in pain’.
In relation to the health-care services, participants described 
how they had to struggle with health-care professionals to be be-
lieved and have their pain taken seriously, as Laura referred (Table 3). 
Similar to what happened in the individual sphere, referrals from pri-
mary and emergency care to specialized pain services did not begin 
until the patient's mobility was severely affected, until the pain man-
ifested itself through physical signs or until they visited the same 
facility several times without improvement. That led to long waiting 
times and delays in receiving an appropriate diagnosis and treatment.
Entering the referral system was the beginning of a tortuous 
journey of hopes and disappointments, a trial/error process that in-
volved trying different treatments with the dream of a pain-free life, 
as the quote from Lola portrays (Table 3).
The Pain Clinic was commonly the place where the long-term 
treatment with opioids was established, although in some cases 
treatment with opioids had started before reaching such specialized 
services, that is in primary health-care facilities. This relationship 
with opioids, frequently initiated at the Pain Clinic, is the focus of 
the next category.
3.2 | Opioids: from blind date to a long-term 
relationship
This category portrays beliefs and perceptions of the benefits and 
drawbacks of treatment with opioids, in addition to struggles to keep 
autonomy and make decisions while being a long-term patient within 
the health system.
It was difficult for participants to recall their first contact with 
opioids, since the common experience of the interviewees was that 
TA B L E  2   Characteristics of the sample





Julia Female 88 Retirement (Housewife) 15 1 y Tapentadol
María Female 40 Total permanent disability 
(Administrative assistant)
22 8 y Tapentadol
Laura Female 55 Sick leave (Administrative assistant) 14 1 y Tramadol (PRN)
Juan Male 72 Retirement (Accountant) 4 4 y Tapentadol
Pilar Female 56 Unemployed (Housewife) 13 13 y Tapentadol
Lola Female 41 Total permanent disability 
(Administrative assistant)
8 8 y Tapentadol
Carlos Male 66 Retirement (Bricklayer) 2 6 mo Tapentadol
Rafael Male 52 Sick leave (Watchman) 5 5 y Tapentadol
Ana Female 41 Unemployed (Housewife) 7 5 y Tramadol
Leticia Female 72 Retirement (Hairdresser) 48 4 y Tramadol y Tapentadol
Sofia Female 46 Total permanent disability (Cleaner) 2 2 y Oxycodone
Alejandro Male 51 Total permanent disability (Bricklayer) 9 4 y Morphine
Roberto Male 72 Retirement (Mechanic) “Long time ago” 2 y Tapentadol
Carmen Female 80 Retirement (Cleaner) 30 “Many years” Tramadol
Hugo Male 52 Unemployed (Carpenter) 5 5 y Morphine
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they had been given little or no information about the new medica-
tion they were prescribed. Consequently, it was difficult for partic-
ipants to distinguish between medications that were in fact opioids 
and other drugs (Table 3).
When the participants realized that they were being prescribed 
opioids, they seemed to accept the treatment due to the intensity of 
pain suffered, despite having the perception that opioids were for 
terminal diseases or relating them with drugs and addiction (Table 3, 
Sofia and Lola quotations). Yet, the perception of opioids as a ‘seri-
ous’ prescription was maintained over time and the fact that their 
acquisition is regulated and controlled was mentioned repeatedly in 
the interviews. There is also a paradox since although some of the 
participants noticed adverse effects of their medication and they re-
flected on the difficulty involved in quitting this long-term treatment 
they weighed in favour of relief. As Sofia (46 years old, 2 years of 
taking oxycodone) said: ‘The truth is that they benefited me, I mean, 
I experienced no strange reactions… well, drowsiness, I am like an 
animal in hibernation, sleeping the whole day’. This understating of 
the effects—drowsiness, in that case—could also be related to the 
lack of information received from health-care professionals. As we 
see in the next quote, Rafael explained commonly experienced ad-
verse effects with opioids like tolerance and dependence without 
naming them specifically:
The point is that coincidentally my illness has become 
worse, and thus, they go parallelly, the increase in 
medication dosage and the increase in pain, and con-
sequently they are increasing the dosage because my 
TA B L E  3   Quotations illustrating categories and theme
Theme: “Living with opioids: dependence and autonomy while 
seeking relief”
Category: “The long pathway to opioids due to the invisibility of 
pain”
Ana, 41 years old, 5 years taking tramadol: “since I was a kid, I've 
always had back pain. I had to come frequently to the hospital, 
always with “lumbago”, mainly “lumbago”.
Carlos, 66 years old, 6 months tapentadol: I have had this problem 
for at least 2 years, and it has been getting worse and worse… I 
wanted the doctors to see me, but there was a long waiting list 
for the specialist. I had to go to the emergency room because I 
couldn't take it anymore. Over and over again to the emergency 
room… and again a dropper, only a dropper… until finally the 
neurosurgeon saw me and said: something must be done here, and 
he sent me here to the Pain Clinic.
Rafael, 52 years old, 5 years taking tapentadol: (talking about a 
previous health problem in the eye) “well, it was more visible, the 
eye was really red, red, red, and people asked me “What happened? 
Did you hit something or what did you do?” […] You could see the 
surprised and shocked faces. But now (with Chronic Pain (CP))… they 
see me so fine, so healthy, and in my inside, I am dying with pain”.
Lola, 41 years old, 8 years taking tapentadol: “My parents took me 
first to the emergency room, and they injected me with morphine, 
and sent me home in an ambulance […] The following day it was 
the same. Another injection and go home. Then, they told me that 
I needed surgery because all my lumbar area was calcified. Then I 
could feel something strange… and they prescribed (small pause) 
morphine, and each time the dosage was increased more, and 
more… and there was no pain relief. They told me there were two 
possible big issues with my type of surgery: instability remaining in 
the backbone or leaving residues of spinal discs, and I had both”.
Category: “Opioids: from blind date to a long-term relationship”
Laura, 55 years old, 1 year taking tramadol: “The doctor told me: 
‘I'm going to prescribe you this medication that I think is going to 
help you’. I found out later that tramadol was an opioid, when I 
searched it on the internet, and people told me: ‘uh, that medicine 
has this and that…’ and I said, ‘that much?’ ‘yes, yes, it's like 
morphine, a derivative’. After this, I saw what it was. But my doctor 
didn't tell me anything.”
Sofia, 46 years old, 2 years taking oxycodone: “I didn't know what 
morphine was. I had heard that it was for drug addicts, that's the 
truth… I didn't know… That's what I have always heard in my house. 
I knew there were patches and all that stuff, but I didn't know for 
what exactly.
Lola, 41 years old, 8 years taking tapentadol: “I was very wrong […] 
I remember that morphine was used with my grandfather before 
dying to relieve his pain and all that stuff, so I never thought I 
would have to take it as they say “as an outpatient treatment, at 
home.” I didn't think it would be like that”.
María, 8 years old, 8 years taking tapentadol: “The morphine has 
caused me… I sleep with a CPAP because of the dryness that 
morphine left me. It caused me sleep apnea. It's left many side-
effects apart from my illness because all the medication that I have 
been taken.
Ana, 41 years old, 5 years taking tramadol: “It's true that opioids 
must have some effect, because I remember that once I ran out 
of them… and I do not know if it was a day or two without taking 
them, and look, I was a physical wreck. I had to lie in bed […] When 
I bought and took them, it made me “Boom!”. I rush out to the 
shops! My husband was shocked! I said: “the pill, look what the pill 
has done to me”.
(Continues)
Theme: “Living with opioids: dependence and autonomy while 
seeking relief”
Category: “What opioids cannot fix”
Ana, 41 years old, 5 years taking tramadol: “For some time I had to 
take anxiolytics. The doctor said that my problem had no solution, 
that I was going to be in pain forever, and I fell apart. But it's true 
that I had no other option. I always try to say to myself: ‘no, come 
on, I'm not going to cry’. This is what I have and that's all there is 
to it. Your mind is the one that has to say: ‘hey, we stop here, I will 
not cry’.
Pilar, 56 years old, 8 years taking tapentadol: “I have little help to 
be honest. I often get angry with him [her husband] because of 
that. All the work is for me. Well, if I'm cleaning, of course he helps 
me, but the housework… he doesn't… he hangs out the washing, 
he helps me with little things like that, he helps me making the bed 
and that's all.
María, 8 years old, 8 years taking tapentadol: “I speak to my very 
close friends and I have to explain that it's morphine and that this 
is what I need for my chronic pain. The society is not… not well 
informed; it's seen like… phew… so bad, she's dying or it must be 
bad if she is taking morphine, and it's not like that”.
Lola, 41 years old, 8 years taking tapentadol: “My family has been 
my lifesaver. Without my father and my mother… look, I am giving 
more importance to them than to my partner. During the day, my 
partner is not with me. He cannot stop working to stay with me… 
it is understandable with just one salary for both of us. If he stops 
working, we cannot live.”
TA B L E  3   (Continued)
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pain is getting worse. The pain I had six months ago is 
now worse. What's happening is it's like my body got 
used to the treatment.
As time passed, the participants appeared to start taking a 
more active attitude towards coping with pain. They described 
how they had learned ways to relieve the pain, including resting, 
losing some weight, exercising (eg swimming, Pilates, walking) and 
taking other medication as needed (eg muscle relaxants, non-ste-
roidal anti-inflammatory drugs). As a reaction to the adverse ef-
fects experienced, they seemed to become progressively more 
active in decision-making related to pain management, and less 
likely to rely exclusively on opioids. In this sense, medication-re-
lated decisions were frequently made without consulting the 
health-care professionals.
It was the bad sweating that I suffered… I read the 
information pamphlet and read sweating was an 
adverse effect and then I wondered, ‘what if I re-
duce a little bit the dose? Let's do an experiment!’ I 
thought ‘maybe the doctor will get angry with me, but 
I am going to experiment’, without quitting totally. I 
thought “I am going to take less than what I was told, 
and I'll see if I can continue without pain and avoid 
that unpleasant sweating” and, right now, indeed, I am 
taking half of the pill. Pilar 
(56 years old, 8 years of taking tapentadol)
But these more active coping strategies to reduce pain did not 
mean total scepticism of opioids. Although the participants complained 
that opioids had not totally eliminated the pain, there was a common 
feeling that they contributed to pain reduction. Sofía said: ‘I was unable 
to take a step, and thanks to starting to take morphine, I can now stand 
up. If I was not taking it, I wouldn't be doing what I am; I do minimal 
things but I at least do them’.
The interviews unveiled that their experience with opioids was 
strongly intertwined with many other life circumstances that lie far 
beyond the scope of action of any medication, as explained in the 
next category.
3.3 | What opioids cannot fix
This category describes different spheres of the participants' lives 
where pain has an impact on a range of economic, familiar and/
or social issues that cannot be addressed through opioids (alone). 
Moreover, these issues may not only be the consequence of pain, but 
what caused it in the first place.
Besides physical limitations and problems, the emotional sphere 
was one of the most strongly affected areas, one that opioids could 
not improve and could even affect negatively. Although in some 
cases reductions in pain led to a better mood, in others, sadness 
due to physical limitations and fear of pain was constant. The next 
quote reflects how pain (and the opioid medication to treat it) had 
disrupted a participant's life and hindered them from doing basic 
daily activities.
I have noticed changes in my mood, you know? I have 
…. a strong personality. I don't know whether it's the 
pill or whether it's the…. Not being able to move as 
I wish, not being able to do things the way I would 
like to. I often feel useless, even with my partner… I 
cannot even have sex as a normal person would, I'm 
limited! Laura 
(55 years old, 1 year of taking tramadol)
In certain cases, these decreases in mood caused by pain resulted 
in mental health comorbidities among the participants. Sometimes this 
was exacerbated when participants were told about the chronicity of 
their illness (Table 3).
To navigate life suffering pain, family support was regarded as 
essential by the participants. However, at the same time, being de-
pendent on their help because of their physical limitations raised 
perceptions of being a burden. Moreover, as described in the 
first category, participants related sometimes feeling neglected, 
as if their families had got used to seeing them in pain. Roberto 
(72 years old, 2 years of taking tapentadol) explained: ‘They help 
me, everything that needs to be done now it's done by my sons-
in-law, poor them, because I can't. But you often feel useless; it 
bothers you that someone is working hard on your behalf, but they 
are very nice’.”
The women participating in the study, regardless of whether 
they were on sick leave or retired, did not identify housework and 
childcare as work, and they mentioned still being the only person 
responsible for housework despite their disabling pain. In addition, 
as the Pilar quote shows in Table 3, women refer to the ‘little things’ 
that their partners do at home as their ‘help’, showing that house-
work is not a shared responsibility from the start.
The participants were aware of the importance of maintaining 
an active social life, and consequently appeared to make an effort to 
do so. This was easier with people who shared the same pathology, 
problems and treatment. Lola (41 years old, 8 years of taking tapen-
tadol) said: ‘I'm part of a Facebook group of people with the same 
surgery as I had. You can hear some people encouraging others; at 
night you know that half of them have been awake like you, and you 
are there… and that cheers you up a little bit. Now, I'm surprised to 
see how many people are taking opioids; indeed, we all take them 
as if it was water. It's much more common than I had ever imagined’. 
Outside ‘pain friends’ circles, the experience was different and par-
ticipants related having felt judged by other people when they dis-
closed they were taking opioids.
Narratives of hard lives where pain was ‘just’ another added dif-
ficulty were a constant in the interviews. Having performed manual 
labour from a young age was common among these patients, and 
sometimes the cause of the illness and the pain. Sofía stated: ‘I was a 
cleaner, and they told me ‘throw this in the garbage’ and I pulled the 
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trolley and that was it… because my back creaked and afterwards 
my back was destroyed from my job as a cleaning woman’. Likewise, 
poor working conditions and living with economic difficulties ap-
peared intertwined as a cause and consequence of pain. As Rafael 
mentioned: ‘At home the only income is my salary. I have to pay the 
mortgage, for my children's studies… well, our income is reduced as 
I'm on sick leave…so I cannot stop working and this situation has led 
me to a state of anxiety’. As is the case with family support, there 
were also differences between men and women related to economic 
difficulties. For two men who participated in the study, the pressure 
of being the breadwinner had negative emotional consequences. For 
three of the women, being economically dependent on their part-
ners led to them having feelings of helplessness. Ana (41 years old, 
5 years of taking tramadol) said: ‘The point is that I get on well with 
my husband, but if I did not get on well with him… what could I do? 
I'm unemployed, I don't have anything, (she gets emotional) ‘my God’.
4  | DISCUSSION
The findings of this study show how the experience of relieving pain 
is a constant struggle among people who suffer from it. Opioids be-
come a way of reducing pain, facilitating physical and social func-
tioning and making a more independent lifestyle possible. However, 
these feelings of independence about physical or social functioning 
are in conflict with concerns of dependence on the medication.
Our results described how the participants' experiences were 
severely influenced by the invisibility of their pain, in the same line 
as findings from previous research.38-40 In this sense, the absence of 
a uniform classification and a validated diagnostic tool in this type 
of pathology hinders the standardization of treatments that bio-
medicalization has brought to other diseases, leading to uncertainty 
in the treatment and diagnosis of the patient, and making it very 
much dependent on the individual perception of the treating phy-
sician.40,41 Thus, as we have seen in our results, the choice of where 
to refer patients and how to treat them is a lengthy trial and error 
process, which is certainly not ideal, and opens the door to disparate 
access to health care.
In this study, the overwhelming majority of participants even-
tually treated in the Pain Clinic after lengthy periods navigating 
through the health-care system were employed in unskilled jobs 
and reported having a basic level of education. We argue, based on 
the discourse of biomedicalization,42 that this overrepresentation 
of patients from lower socio-economic backgrounds in our study is 
because the quest for a diagnosis and treatment could presumably 
be ‘easier’ and ‘shorter’ for those who can afford private medical 
care and can skip the mutual referral system between the GPs and 
specialists of the public health system. The increase in stratifying 
fee-for-service options, which is another characteristic of biomedi-
calization, enables the more wealthy to address their illness, circum-
venting waiting times for medical procedures and obtaining access 
to multidisciplinary intervention in the biological, psychological and 
social aspects of their chronic pain condition.43
In relation to experiences with opioids, our findings show that 
opioids were insufficient to relieve all the pain, as examples of 
limitations to daily life because of pain were an important part 
of the participants' narratives. However, the participants' per-
ception was also that their physical functioning and quality of life 
had improved thanks to opioids. These contradictions between 
perceived improvement and narratives of severe limitations were 
recurrent in the participants' accounts. As other authors have 
shown,18 due to a lack of information or misinformation, patient 
expectations regarding the results they can expect from this treat-
ment may be unrealistic. In line with this, the difficulties the par-
ticipants found to identify side effects, tolerance or dependence 
were also noteworthy. Exemplifying the heterogeneity in the pro-
duction, distribution and access to biomedical knowledge that is 
part of biomedicalization, the majority of the participants stated 
that they had looked on the Internet to be informed about opioids 
and their consequences, and in many cases developed individual 
strategies to deal with the side effects they experienced. Having 
to look oneself for information about the treatment prescribed 
reflects a shift in responsibility for care practices, which is put 
increasingly on healthcare-users, this change being another es-
sential component of biomedicalization.42 Even if access to medi-
cal knowledge is improved thanks to new technologies, the ability 
to benefit from that information depends strongly on individual 
health literacy levels. According to a report published by the 
WHO in 2013,44 more than half of the Spanish population have in-
adequate or problematic health literacy levels.44 Furthermore, the 
population with a lower social status have much higher propor-
tions of limited health literacy levels.45,46 In addition, increased 
responsibility for their own healthcare driven by biomedicaliza-
tion processes leads to self-blame for any health problems that 
arise. As seen in some of the quotations of the participants, they 
blamed their pain on things they have done, like pulling too much 
weight or waiting too long to seek medical care instead of placing 
the blame on their working conditions when evidence shows that 
unskilled workers have the highest prevalence of musculoskeletal 
disorders, a large proportion of which can certainly be attributed 
to working conditions.47
Finally, another basic process of biomedicalization is the pro-
duction of new identities and reframing of old ones by technosci-
entific means. In this sense, the social role and identity of chronic 
patients for whom no cure is available despite all the technosci-
entific advances remain a challenge due to the invisibility of pain. 
In the social arena, the participants of our study felt stigmatized 
in several ways. They felt neglected due to the invisibility of pain. 
Many patients with CP do not present any visible symptoms and 
remain stoic when they feel pain, resulting in a lack of empathy 
from friends.48 In addition, the participants felt stigmatized be-
cause of the treatment with opioids. Ljungvall et al26 described 
how participants experienced being stigmatized because of their 
repeated contacts with medical care workers, who see them as 
drug-seeking behaviours. However, in our study, the partici-
pants experienced this stigmatization by relatives and friends 
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who expressed many concerns and prejudices about opioids. The 
negative consequences of ‘double’ or ‘layered’ stigmatized condi-
tions—‘CP sufferer’ and ‘drug addict’—have also been described by 
Dassieu et al,31 who suggest that being doubly stigmatized rein-
forces people's isolation as well as their experience of loss of dig-
nity. Interestingly, in our study, the participants referred to sharing 
their experience of CP and opioid treatments with ‘pain friends’, 
among whom treatment with opioids was common. Peer support 
has been shown49 to reduce social isolation, encourage shared 
experiential learning and foster psychosocial well-being. Thus, 
‘taking charge’ of their health, understood in biomedicalization as 
responsibility for care practices, by means of active coping strat-
egies such as maintaining an active social life with ‘pain friends’ 
was crucial for the health of the participants, as reported in the 
literature.18
As previously described,28,50 family support was also very 
important for the participants with regard to the management 
of their pain. Some, however, considered themselves to be a bur-
den due to their physical disability. This feeling could result from 
a sense of inequity or imbalance if they perceive that what they 
receive outweighs what they provide.51 In addition, some partici-
pants described feelings of depression and uncertainty, as well as 
a decreased sense of autonomy and/or self-confidence because 
of both physical dependence and economic dependence. These 
worries emerge strongly in this study. As a result, physicians often 
find themselves trying to bridge the gap between the chronic pain 
patient's expectations for effective pain relief and the harsh bio-
medical reality.52 However, medication, opioids in these cases, is 
not enough to solve problems of another nature that in some cases 
predated the pain.
5  | CLINIC AL IMPLIC ATIONS
Greater awareness should be raised among health-care profession-
als about the experiences of patients with CP to counterbalance the 
negative effects of the invisibility of pain such as the lack of credibil-
ity given to symptoms expressed by patients and delays in access to 
diagnosis and treatment. This would shorten and improve patients' 
relationship with health-care services.
Regarding information about long-term treatment with opioids, 
there is a need to improve the quantity and quality of information 
provided to patients. Furthermore, health-care professionals should 
be aware of the extended use of alternative information sources like 
Internet or peers among patients who experience CP, to ensure they 
are able to assess the credibility of the information they access and 
are able to understand and make use of this information, that is to 
ensure they have sufficient health literacy levels.
Finally, an interdisciplinary approach and health-care team that 
includes social workers and psychologists is essential to address all 
those spheres of life affected by and affecting CP experiences and 
where opioids have little or no effect.
6  | METHODOLOGIC AL CONSIDER ATIONS
As previously described, several steps were taken to strengthen the 
trustworthiness of the findings. These do, however, need to be inter-
preted with some limitations in mind. Concerning transferability, it is 
important to consider the context where this study was conducted: 
a group of individuals with chronic pain, treated in a Pain Clinic of 
the Spanish health-care system. With this in mind, we consider that 
the results from this study could be relevant for understanding the 
experiences of people with CP who are taking long-term treatment 
with opioids in other countries with similar sociocultural aspects and 
health-care systems, since the consequences they face and concerns 
they have about opioids may be the same.
Regarding credibility, we chose participants with different sex/
gender, ages and experiences to increase the likelihood of shedding 
light on the research question. What is more, the open-ended ques-
tions made it possible to share both positive and negative experi-
ences. However, people who were at the beginning of the illness 
process may not have been reached, since we recruited participants 
via the Pain Clinic. Nonetheless, as we discuss in this study, CP is 
an illness that implies a long and difficult process before being be 
diagnosed and treated. Thus, opioids as a treatment are usually 
prescribed to those who have been suffering pain for a long-term 
period.
Another limitation of this study is that, although the results sug-
gested gender differences in the patients' experiences with both 
CP and its treatment with opioids, the data were not rich enough to 
support a deep analysis and the elaboration of conclusions. Further 
research with this aim is required.
7  | CONCLUSIONS
The participants' experiences were strongly shaped by the invisibil-
ity of pain, which led to a long-term relationship with the health-care 
system and different forms of stigmatization. The participants made 
up for the limited information received from health-care profession-
als by surfing the Internet or asking peers. Yet, they showed limited 
knowledge about side effects and the long-term consequences of 
the treatment.
The burden of social determinants of health was in-
creased by CP and at the same time a source of complications in CP 
experiences.
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